Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 39 Breast Neoplasms 24 Neoplasms 12 Prostatic Neoplasms 11 Triple Negative Breast Neoplasms 9 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Pancreatic Neoplasms 7 Neoplasm Metastasis 7 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Metastatic Castration-resistant Prostate Cancer 5 Fanconi Anemia, Complementation Group D1 5 Small Cell Lung Carcinoma 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Solid Tumors 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Prostatic Neoplasms, Castration-Resistant 2 Colorectal Neoplasms 2 Carcinoma 2 Advanced Solid Tumours 2 Advanced Solid Tumor 2 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1

Interventions

olaparib 1 mitazalimab 1 TAK-659 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Solid Neoplasms × olaparib × Clear all

NCT03742895 2026-05-15

MK-7339-002

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Advanced Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡